MORE than half of patients diagnosed with non-Hodgkin lymphoma (NHL) are now surviving the cancer thanks to improved diagnosis and treatment, campaigners have said

Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy

WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6 million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber

In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certain

Faster approvals needed for coverage by provincial drug plans: Lymphoma Foundation Canada TORONTO, April 24, 2013 /CNW/ - The recent approval by Health Canada of a highly effective new treatment for non-Hodgkin

( John Theurer Cancer Center ) John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm

Non-Hodgkin lymphoma is the seventh most common form of cancer in the United States, and doctors may have found a new way to treat it. Some forms of the lymphoma respond well to treatment, but others are stubborn and aggressive. Now, a new discovery may change the way doctors treat the most difficult cases. Researchers are using the concept that in order to kill the enemy, you must target the

“What doesn’t kill you makes you stronger

NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the